Perrigo (PRGO) Fundamentals 2026 — Revenue Analysis | SniperIQ
Perrigo (PRGO) is a IE-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Perrigo's market cap?
Perrigo (PRGO) has a market capitalization of approximately
What is Perrigo's P/E ratio?
Perrigo's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Perrigo?
Perrigo runs a net profit margin of -43.5%, a gross margin of 34.2%, and an operating margin of 5.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Perrigo generate?
Perrigo reported revenue of $4.3B for fiscal year 2025, with net income of -
Does Perrigo pay a dividend?
Perrigo offers a trailing dividend yield of about 10.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Perrigo financially healthy?
Perrigo carries a debt-to-equity ratio of 1.52x and a current ratio of 2.72x, with a market beta of 0.52. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Perrigo a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Perrigo (PRGO) the key facts are: market cap
Track Perrigo's full fundamentals live
Get Perrigo's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.